1c:{"metadata":[["$","title","0",{"children":"NIH VideoCast - FDA-NCI Workshop on Therapeutic Cancer Vaccines"}],["$","meta","1",{"name":"description","content":"FDA and NCI are holding a public workshop intended to facilitate the development of safe and effective cancer vaccine by optimizing early phase clinical trials based on lessons learned from completed Phase III studies. \n \n

\n \nIn this workshop, the role of randomized Phase II clinical trials and adaptive study designs will be discussed. Furthermore, the workshop will emphasize the importance of monitoring immune responses in early phase trials in order to optimize immunological therapies and incorporating pretreatment biomarkers in early phase clinical studies that could predict the effect of specific treatment for patients (predictive biomarkers) in order to identify a population likely to benefit. \n

\n\n\nFor more information, visit
\nhttp://web.ncifcrf.gov/events/cancervaccine/default.asp
\n"}],["$","meta","2",{"name":"publisher","content":"National Institutes of Health"}],["$","meta","3",{"property":"og:title","content":"NIH VideoCast - FDA-NCI Workshop on Therapeutic Cancer Vaccines"}],["$","meta","4",{"property":"og:description","content":"FDA and NCI are holding a public workshop intended to facilitate the development of safe and effective cancer vaccine by optimizing early phase clinical trials based on lessons learned from completed Phase III studies. \n \n

\n \nIn this workshop, the role of randomized Phase II clinical trials and adaptive study designs will be discussed. Furthermore, the workshop will emphasize the importance of monitoring immune responses in early phase trials in order to optimize immunological therapies and incorporating pretreatment biomarkers in early phase clinical studies that could predict the effect of specific treatment for patients (predictive biomarkers) in order to identify a population likely to benefit. \n

\n\n\nFor more information, visit
\nhttp://web.ncifcrf.gov/events/cancervaccine/default.asp
\n"}],["$","meta","5",{"property":"og:url","content":"https://uat.d1rkikwu4q8tg.amplifyapp.com/watch/9e34e309-d5db-11f0-9cf9-12c45c580ad9"}],["$","meta","6",{"property":"og:site_name","content":"NIH VideoCast"}],["$","meta","7",{"property":"og:image","content":"https://nihcit.rev.vbrick.com/api/v2/media/videos/thumbnails/5abe43b3-9323-4b7e-83d6-6f84d1671853.jpg"}],["$","meta","8",{"property":"og:type","content":"website"}],["$","meta","9",{"name":"twitter:card","content":"summary_large_image"}],["$","meta","10",{"name":"twitter:title","content":"NIH VideoCast - FDA-NCI Workshop on Therapeutic Cancer Vaccines"}],["$","meta","11",{"name":"twitter:description","content":"FDA and NCI are holding a public workshop intended to facilitate the development of safe and effective cancer vaccine by optimizing early phase clinical trials based on lessons learned from completed Phase III studies. \n \n

\n \nIn this workshop, the role of randomized Phase II clinical trials and adaptive study designs will be discussed. Furthermore, the workshop will emphasize the importance of monitoring immune responses in early phase trials in order to optimize immunological therapies and incorporating pretreatment biomarkers in early phase clinical studies that could predict the effect of specific treatment for patients (predictive biomarkers) in order to identify a population likely to benefit. \n

\n\n\nFor more information, visit
\nhttp://web.ncifcrf.gov/events/cancervaccine/default.asp
\n"}],"$L22","$L23","$L24"],"error":null,"digest":"$undefined"}